Endologix Inc fka ELGXQ

[Muskett50]

[Muskett50]

[Muskett50]

[Muskett50]

[Muskett50]

quiet here

[surf1944]

9:01AM Endologix announces publication of consolidated long-term anatomical fixation clinical trial results (ELGX) 4.70 : Co announces the publication of consolidated results from its prospective, multicenter clinical trials of the Company's Powerlink stent graft for the endovascular repair of abdominal aortic aneurysms using an anatomical fixation technique. The trial results demonstrate no aneurysm ruptures, no conversions to open repair, no device migrations, no stent fractures, no graft fatigue, no junctional endoleaks, no transgraft endoleaks, and 100% freedom from aneurysm-related mortality for up to five years post-implant. In addition, core lab evaluations found a low rate of limb occlusion, with significantly reduced or stable aneurysm sacs in 95% and 93% of patients at one year and five years, respectively.

[TRIXXX]

Other medical plays include APT.
Also AXTG is in play!

[TRIXXX]

Conference call highlights.
-42% global revenue growth
-first full quarter of positive cash flow
-first full six months of positive cash flow
-good position to expand in the aortic stent graft market
-sales force expanding and taking market share
-still plenty of opportunity for further growth
-2010 international market will be expanded into
-record revenue 13.2m in quarter
-gross margin improvements from volume efficiencies
-increase in cash balance
-raised revenue guidance
-IntuiTrac has an advantage in ease of use and expansion with new physicians
-competitors are Medtronic, W. L. Gore & Associates and Cook Group Inc.-but their devices are bigger and the smaller device of endologix has an advantage
-8% yearly procedure growth
All great news.

[r3algood]

ELGX chart:

Looking good!

[TRIXXX]

Welcome to the Endologix board.
These are truly exciting times for this company.
Their main product is a stent used to bypass abdominal aortic aneurysms. This stent is patented and is superior to the other stents on the market.
They are significantly growing their market share of abdominal aortic stents and will be competing with Medtronic(MDT) and the Cook Group, Inc.(a private company)
Their stock price has been on a tear appreciating over 100% in the last six months.
Earnings are due out on July 22, 2009.